How Metabolomics Findings Can Drive New Therapeutic Approaches? (Volume II)
A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Metabolomic Profiling Technology".
Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 3168
Special Issue Editor
2. INSERM 1253, iBrain, University of Tours, Inserm, 37000 Tours, France
Interests: metabolomic analysis, amyotrophic lateral sclerosis; biomarkers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Metabolism alteration is thoroughly involved in diverse pathologies from neurological diseases to cancer, either as a direct consequence of primary pathophysiological mechanisms or as an indirect process of disease evolution and/or patient management. For example, modifications of lipid metabolism, mitochondrial impairment, or glucose intolerance have largely been described in neurodegenerative diseases, as well as glycolysis modification in cancer. Omics studies have progressed in their technical aspects over recent years and have also led to putative clinical consequences. They have helped improve our knowledge of the metabolic pathways involved in these diseases and have provided hypotheses about their link with the main pathophysiological pathways like inflammation or oxidative stress. With regard to diseases with poor or ineffective therapeutics, many research groups are focused on the development of new strategies of treatment or new compounds based on metabolic targets. Importantly, metabolic perturbations linked to diseases or to new treatments or specific diets (i.e., ketogenic diet, vitamin supplementation, etc.) may play a prognostic role in these diseases.
In this context, it seems crucial to know how the increased practice of “omics” (mainly metabolomics and lipidomics) in in vitro, in vivo, and clinical studies may improve our capacity to identify new therapeutic targets and to follow the underlying, and perhaps hidden, effects of a given treatment. We should also pay attention to the subtle effects of changing diets, for example using this strategy in addition to other drugs or to use metabolism status to determine the subgroups of patients. Thus, omics approaches have many interests in healthcare, mainly as diagnosis and prognosis biomarkers—but we must keep in mind our ability to develop and monitor new therapeutic strategies based on their findings.
Accordingly, metabolomics and lipidomics studies that have enabled the characterization of subgroups of patients in clinical trials merit discussion in this Special Issue. Studies on metabolomics/lipidomics approaches that have identified therapeutic targets or studies evaluating, through in vitro or in vivo experiments, metabolic treatments directly targeting a metabolic pathway (glucose or lipid metabolism, respiratory chain, etc.) are relevant for highlighting the new opportunities in omics. Finally, reports of the deleterious, papers on the indirect consequences of metabolic disturbances associated with a treatment or a diet and that could play an important prognosis role are sought after for this Special Issue.
Prof. Dr. Helene Blasco
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metabolomics
- lipidomics
- therapeutics
- endophenotypes
- disease monitoring
